|
|||||
|
|
Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy |
|
| Authors: | Misako Matsumoto Yohei Takeda |
| Affiliation: | 1. Department of Vaccine Immunology, Graduate School of Medicine, Hokkaido University , Sapporo, Japan;2. Nebuta Research Institute for Life Sciences, Aomori University , Aomori, Japan matumoto@pop.med.hokudai.ac.jp;4. Department of Vaccine Immunology, Graduate School of Medicine, Hokkaido University , Sapporo, Japan |
| Abstract: | ABSTRACT IntroductionActivation of innate immune system is a key step to develop anti-tumor immunity. Antigen-presenting dendritic cells (DCs) cross-present tumor-associated antigens to cytotoxic CD8+ T cells (CTLs). Signaling from pattern-recognition receptors (PRRs) in DCs is required to induce tumor-specific CTLs. |
| Keywords: | Adjuvant cancer immunotherapy checkpoint inhibitors cross-priming dendritic cells double-stranded RNA innate immunity Toll-like receptor 3 |